Perceptive Advisors SEPN Position
Exited8-Fund ConvergencePerceptive Advisors exited their position in Septerna, Inc. (SEPN) in Q1 2025, after holding the stock for 2 quarters.
The position was first reported in Q4 2024 and has been tracked across 2 quarterly 13F filings.
SEPN is a convergence signal: 8 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Septerna, Inc.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.
Full company profile →Short Interest
8.0%
5.9 days to cover
Perceptive Advisors SEPN Position History
Frequently Asked Questions
Does Perceptive Advisors own SEPN?
No. Perceptive Advisors exited their position in Septerna, Inc. (SEPN) in Q1 2025. They previously held the stock for 2 quarters.
How many hedge funds own SEPN?
8 specialist biotech hedge funds currently hold SEPN, including RA Capital Management, Driehaus Capital, BVF Partners and 5 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Perceptive Advisors first buy SEPN?
Perceptive Advisors's position in SEPN was first reported in Q4 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Perceptive Advisors's SEPN position increasing or decreasing?
Perceptive Advisors completely exited their SEPN position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
SEPNCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Perceptive AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →